Literature DB >> 7863536

Mechanism of caffeine modulation of the antitumor activity of adriamycin.

Y Sadzuka1, E Mochizuki, Y Takino.   

Abstract

We examined the effects of a combination of adriamycin (ADR) and caffeine on DNA and protein biosynthesis and on the activities of DNA polymerase alpha and beta in normal and tumor tissue. The decrease in DNA and protein biosynthesis in tumor produced by caffeine combined with ADR were 2.5 and 2.4 times greater, respectively, compared with ADR alone. The combination of caffeine and ADR enhanced the decrease in DNA polymerases activities in the tumor which was induced by ADR, the decreases being 1.8 and 1.6 times greater, respectively, than that of ADR alone. In contrast, these ADR-induced changes in normal tissues were not enhanced by the combination with caffeine. The combination with caffeine had no effect on ADR concentration in normal tissues, but in the tumor, it increased the ADR concentration to 2.1 times that of ADR alone. In vitro, ADR efflux from Ehrlich ascites carcinoma cells was significantly inhibited by exposure to caffeine. These findings indicate that the effect of caffeine on ADR concentration in the cell plays an important role in the mechanism by which caffeine enhances ADR antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7863536     DOI: 10.1016/0378-4274(94)03154-y

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  5 in total

1.  Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.

Authors:  Rui Ding; Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

2.  Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect.

Authors:  Wonku Kang; Michael Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

3.  Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.

Authors:  Y Sadzuka; Y Egawa; T Sugiyama; H Sawanishi; K Miyamoto; T Sonobe
Journal:  Jpn J Cancer Res       Date:  2000-06

4.  1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin.

Authors:  Y Sadzuka; A Iwazaki; T Sugiyama; T Sawanishi; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1998-02

5.  Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity.

Authors:  Y Sadzuka; A Iwazaki; A Miyagishima; Y Nozawa; S Hirota
Journal:  Jpn J Cancer Res       Date:  1995-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.